The collaboration draws on ResearchDx's ability to design, produce, and validate tests, and CompanDx's Distiller platform to deliver small composite biomarker signatures from complex data of high dimensionality.

Under the terms of the multi-year agreement, the partners will advance diagnostic tests, from biomarker discovery to test validation, applying CompanDx's Risk Distiller bioinformatics tool and CRL's CLIA-certified laboratory services.

The partners said they will collaborate on the development of biomarker panels and companion diagnostics for pharmaceutical, biotech, and academic clients worldwide.

The 31-gene signature, used to predict the time to cancer metastasis after initial surgery and biopsy, has been validated by CompanDX researchers in four different datasets, according to the company.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.